Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.
The National Institutes of Health (NIH) is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. The majority of NIH facilities are located in Bethesda, Maryland and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.
The National Institute of Allergy and Infectious Diseases (NIAID) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
The Center for Biologics Evaluation and Research (CBER) is one of six main centers for the U.S. Food and Drug Administration (FDA), which is a part of the U.S. Department of Health and Human Services. The current Director of CBER is Peter Marks, M.D., PhD. CBER is responsible for assuring the safety, purity, potency, and effectiveness of biologics and related products. Not all biologics are regulated by CBER. Monoclonal antibodies and other therapeutic proteins are regulated by the FDA Center for Drug Evaluation and Research (CDER).
Rocky Mountain Laboratories (RML) is part of the NIH Intramural Research Program and is located in Hamilton, Montana. Operated by the National Institute of Allergy and Infectious Diseases, RML conducts research on maximum containment pathogens such as Ebola as well as research on prions and intracellular pathogens such as Coxiella burnetti and Francisella tularensis. RML operates one of the few Biosafety level 4 laboratories in the United States, as well as Biosafety level 3 and ABSL3/4 laboratories.
The NIH Intramural Research Program (IRP) is the internal research program of the National Institutes of Health (NIH), known for its synergistic approach to biomedical science. With 1,200 Principal Investigators and over 4,000 Postdoctoral Fellows conducting basic, translational, and clinical research, the NIH Intramural Research Program is the largest biomedical research institution on earth. The unique funding environment of the IRP facilitates opportunities to conduct both long-term and high-impact science that would otherwise be difficult to undertake. With rigorous external reviews ensuring that only the most outstanding research secures funding, the IRP is responsible for many scientific accomplishments, including the discovery of fluoride to prevent tooth decay, the use of lithium to manage bipolar disorder, and the creation of vaccines against hepatitis, Hemophilus influenzae (HIB), and human papillomavirus (HPV). In addition, the IRP has also produced or trained 21 Nobel Prize-winning scientists.
Susan G. Amara is an American professor of neuroscience and is the Scientific Director of the National Institute of Mental Health. Dr. Amara is an elected member of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science. She is a Past-President of the Society for Neuroscience. Dr. Amara has a B.S. in Biological Sciences from Stanford University and a Ph.D. in Physiology and Pharmacology from the University of California, San Diego.
Keiko Ozato is a Japanese American geneticist whose research has focused on gene regulation in the developing immune system; She is best known for her contributions to immunogenetics and epigenetics in isolating the IRF8 transcription factor that aids humans in fighting off disease and for identifying the BRD4 protein that regulates cellular and viral genes that can invoke epigenetic memory. She is Senior Investigator at the Section on Molecular Genetics of Immunity at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health in Bethesda, Maryland and a professor at the University of Maryland, College Park.
Bernard Moss is a virologist at the National Institute of Allergy and Infectious Diseases, part of the United States National Institutes of Health. He is the Chief of the NIAID Laboratory of Viral Diseases and of the NIAID Genetic Engineering Section. He is known for his work on poxviruses.
Akiko Iwasaki is the Waldemar Von Zedtwitz Professor in the Department of Immunobiology and a Professor in the Department of Molecular, Cellular, and Developmental Biology at Yale University. She is also a principal investigator at the Howard Hughes Medical Institute. Her research interests include innate immunity, autophagy, inflammasomes, sexually transmitted infections, herpes simplex virus, human papillomavirus, respiratory virus infections, influenza infection, T cell immunity, and commensal bacteria.
Julie E. Ledgerwood is an American allergist and immunologist, who is the chief medical officer and serves as chief of the Clinical Trials Program at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in Bethesda, Maryland. She is a Doctor of Osteopathic Medicine.
Thomas Charles Merigan was born January 18,1934 in San Francisco. He is an American virologist and the George E. and Lucy Becker Professor of Medicine, Emeritus at the Stanford University School of Medicine. Merigan's research first focused on viral pathogenesis, basic and clinical studies of interferon, and then developing the first systemically active antiviral drugs including those effectively treatIng HIV/AIDS, herpesviruses and hepatitis B. He is also credited with helping to develop the use of interferons as antiviral, immunomodulating and antitumor therapies. Merigan joined the Stanford faculty in 1963 and assumed full emeritus status in 2007. In 2004 he was also identified as one of the 250 most cited investigators in clinical medicine over the last 20 years by the Institute for Scientific Information. He had over 100 postdoctoral fellows, students and visiting scientists with whom he published 577 papers, 24 books and published symposia, and held 11 US patents. There has been over 30,000 citations of his publications. Two of his books went into multiple editions- one into a 4th edition and the other into a 3rd. His students have become leaders in the fields of infectious diseases and microbiology both in the US and the world. He was a board member of 28 journals and a member of 23 learned societies. He told his life story in a book entitled Pioneering Viral Therapy,a Life in Academic Medicine, published by Amazon/Kindle/CreateSpace in 2017.
John I. Gallin is an American medical researcher who has contributed to the understanding of innate immunity but especially chronic granulomatous disease, a phagocyte disorder. Gallin was appointed director of the NIH Clinical Center on May 1, 1994, and served until January 8, 2017. He serves as the chief scientific officer for the Clinical Center and associate director for Clinical Research at the National Institutes of Health.
Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is the Shutzer Assistant Professor at the Harvard Radcliffe Institute and assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. She joined Harvard following six years at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, National Institutes of Health based in Bethesda, Maryland. She earned a PhD in microbiology and immunology from the University of North Carolina at Chapel Hill in 2014. Appointed to the VRC in 2014, Corbett was the scientific lead of the VRC's Coronavirus Team, with research efforts aimed at propelling novel coronavirus vaccines, including a COVID-19 vaccine. In February 2021, Corbett was highlighted in the Time's "Time100 Next" list under the category of Innovators, with a profile written by Anthony Fauci.
Catharine "Katy" Mans Bosio is an American biologist. She is a senior investigator and chief of the immunity to pulmonary pathogens section at the National Institute of Allergy and Infectious Diseases.
Vanessa M. Hirsch is a Canadian-American veterinary pathologist and scientist. She is a senior investigator and chief of the nonhuman primate virology section at the National Institute of Allergy and Infectious Diseases. Hirsch researches AIDS pathogenesis, the evolution and origins of primate lentiviruses, and HIV vaccine development.
Barbara K. Felber is an American biologist specialized in human retrovirus pathogensis and gene regulation. She is a senior investigator in the vaccine branch at the National Cancer Institute.
Silvana Romina Goldszmid is an Argentine-American biologist researching tumor immunology. She is an NIH Stadtman Investigator at the National Cancer Institute.
Dr. Michael J. Lenardo, is the Chief of the Molecular Development and Immune System Section and the founder and co-Director of the Clinical Genomics Program at the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH). Trained as a geneticist and molecular immunologist, his research examines how cells of the immune system defend themselves against various pathogens, including viruses and bacteria. His research has investigated genetic abnormalities in the immune system, non-apoptotic mechanisms of cell death, genetic diseases of immune homeostasis and autoimmunity, and development of novel diagnostics and therapeutics for diseases of the immune system. Lenardo's contributions to science and medicine have shown the possibilities of genomic research in developing precision medicine diagnoses and treatments for disease in humans. In 2006 he was appointed Officer of the Most Excellent Order of the British Empire (O.B.E.) by Queen Elizabeth II. In 2019 he was inducted into the National Academies of Sciences and the National Academy of Medicine, considered among the highest honors awarded to a U.S scientist and medical researcher respectively.
Mary Elizabeth Daucher is an American biologist serving as the acting chief of the vaccine production program laboratory at Vaccine Research Center of the National Institute of Allergy and Infectious Diseases.
